Trends in Prescribing of and Spending on Digoxin in General Practice in England

0

200,000

400,000

600,000

800,000

1,000,000

1,200,000

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Quarter to

Item

s

£0

£500,000

£1,000,000

£1,500,000

£2,000,000

£2,500,000

£3,000,000

£3,500,000

£4,000,000

NIC

(£)

Items NIC

© Copyright NHSBSA 2009

Trends in Prescribing of Thiazides and Related Diuretics in General Practice in England

0

1,000,000

2,000,000

3,000,000

4,000,000

5,000,000

6,000,000

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Quarter to

Item

s

Bendroflumethiazide Indapamide Others

© Copyright NHSBSA 2009

Trends in Spending on Thiazides and Related Diuretics in General Practice in England

0

2,000,000

4,000,000

6,000,000

8,000,000

10,000,000

12,000,000

14,000,000

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Quarter to

NIC

(£)

Bendroflumethiazide Indapamide Others

© Copyright NHSBSA 2009

Trends in Prescribing of Bendroflumethiazide Tabs/Caps in General Practice in England

0

1,000,000

2,000,000

3,000,000

4,000,000

5,000,000

6,000,000

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Quarter to

Item

s

2.5mg 5mg

© Copyright NHSBSA 2009

Trends in Prescribing of Spironolactone Caps/Tabs in General Practice in England

0

50,000

100,000

150,000

200,000

250,000

300,000

350,000

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Quarter to

Item

s

25mg 50mg 100mg

© Copyright NHSBSA 2009

Trends in Prescribing of Potassium-sparing Diuretics in General Practice in England

0

100,000

200,000

300,000

400,000

500,000

600,000

Sep

-03

Dec-03

Mar-04

Jun

-04

Sep

-04

Dec-04

Mar-05

Jun

-05

Sep

-05

Dec-05

Mar-06

Jun

-06

Sep

-06

Dec-06

Mar-07

Jun

-07

Sep

-07

Dec-07

Mar-08

Jun

-08

Sep

-08

Quarter to

Item

s

Spironolactone Amiloride

Eplerenone Triamterene

© Copyright NHSBSA 2009

Trends in Spending on Potassium-sparing Diuretics in General Practice in England

0

500,000

1,000,000

1,500,000

2,000,000

2,500,000

3,000,000

3,500,000

Sep

-03

Dec-03

Mar-04

Jun-04

Sep

-04

Dec-04

Mar-05

Jun-05

Sep

-05

Dec-05

Mar-06

Jun-06

Sep

-06

Dec-06

Mar-07

Jun-07

Sep

-07

Dec-07

Mar-08

Jun-08

Sep

-08

Quarter to

NIC

(£)

Spironolactone Amiloride

Eplerenone Triamterene

© Copyright NHSBSA 2009

Trends in Prescribing of Potassium-sparing Diuretics with Other Diuretics in General Practice in England

0

100,000

200,000

300,000

400,000

500,000

600,000

700,000

800,000

900,000

1,000,000

Sep

-03

Dec-03

Mar-04

Jun

-04

Sep

-04

Dec-04

Mar-05

Jun

-05

Sep

-05

Dec-05

Mar-06

Jun

-06

Sep

-06

Dec-06

Mar-07

Jun

-07

Sep

-07

Dec-07

Mar-08

Jun

-08

Sep

-08

Quarter to

Item

s

Amiloride + loop diuretic Amiloride + thiazide Triamterene + thiazide Others

© Copyright NHSBSA 2009

Trends in Spending on Potassium-sparing Diuretics with Other Diuretics in General Practice in England

0

500,000

1,000,000

1,500,000

2,000,000

2,500,000

3,000,000

3,500,000

4,000,000

Sep

-03

Dec-03

Mar-04

Jun

-04

Sep

-04

Dec-04

Mar-05

Jun

-05

Sep

-05

Dec-05

Mar-06

Jun

-06

Sep

-06

Dec-06

Mar-07

Jun

-07

Sep

-07

Dec-07

Mar-08

Jun

-08

Sep

-08

Quarter to

NIC

(£)

Amiloride + loop diuretic Amiloride + thiazide Triamterene + thiazide Others

© Copyright NHSBSA 2009

Trends in Prescribing of and Spending on Amiodarone in General Practice in England

0

50,000

100,000

150,000

200,000

250,000

300,000

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Quarter to

Item

s

£0

£200,000

£400,000

£600,000

£800,000

£1,000,000

£1,200,000

£1,400,000

£1,600,000

£1,800,000

£2,000,000

NIC

(£)

Items NIC (£)

© Copyright NHSBSA 2009

Trends in Prescribing of Beta-adrenoceptor Blocking Drugs (including Combinations) in General Practice in England

0

1,000,000

2,000,000

3,000,000

4,000,000

5,000,000

6,000,000

7,000,000

8,000,000

Sep

-03

Dec-03

Mar-04

Jun

-04

Sep

-04

Dec-04

Mar-05

Jun

-05

Sep

-05

Dec-05

Mar-06

Jun

-06

Sep

-06

Dec-06

Mar-07

Jun

-07

Sep

-07

Dec-07

Mar-08

Jun

-08

Sep

-08

Quarter to

Item

s

Atenolol Bisoprolol Propranolol Metoprolol SotalolCarvedilol Nebivolol Others Combinations

© Copyright NHSBSA 2009

Trends in Spending on Beta-adrenoceptor Blocking Drugs (including Combinations) in General Practice in England

0

5,000,000

10,000,000

15,000,000

20,000,000

25,000,000

30,000,000

Sep

-03

Dec-03

Mar-04

Jun

-04

Sep

-04

Dec-04

Mar-05

Jun

-05

Sep

-05

Dec-05

Mar-06

Jun

-06

Sep

-06

Dec-06

Mar-07

Jun

-07

Sep

-07

Dec-07

Mar-08

Jun

-08

Sep

-08

Quarter to

NIC

(£)

Atenolol Bisoprolol Propranolol Metoprolol SotalolCarvedilol Nebivolol Others Combinations

© Copyright NHSBSA 2009

Trends in Prescribing of Alpha-adrenoceptor Blocking Drugs in General Practice in England

0

200,000

400,000

600,000

800,000

1,000,000

1,200,000

1,400,000

1,600,000

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Quarter to

Item

s

Doxazosin Prazosin Terazosin Others

© Copyright NHSBSA 2009

Trends in Spending on Alpha-adrenoceptor Blocking Drugs in General Practice in England

0

5,000,000

10,000,000

15,000,000

20,000,000

25,000,000

30,000,000

Sep

-03

Dec-03

Mar-04

Jun

-04

Sep

-04

Dec-04

Mar-05

Jun

-05

Sep

-05

Dec-05

Mar-06

Jun

-06

Sep

-06

Dec-06

Mar-07

Jun

-07

Sep

-07

Dec-07

Mar-08

Jun

-08

Sep

-08

Quarter to

NIC

(£)

Doxazosin Prazosin Terazosin Others

© Copyright NHSBSA 2009

% Ratio of Prescribing of ACE Inhibitors vs Angiotensin-II Receptor Antagonists

0%

20%

40%

60%

80%

100%

Sep

-03

Dec-03

Mar-04

Jun

-04

Sep

-04

Dec-04

Mar-05

Jun

-05

Sep

-05

Dec-05

Mar-06

Jun

-06

Sep

-06

Dec-06

Mar-07

Jun

-07

Sep

-07

Dec-07

Mar-08

Jun

-08

Sep

-08

Quarter to

% o

f al

l ite

ms

ACE Inhibitors Angiotensin-II Receptor Antagonists

© Copyright NHSBSA 2009

% Ratio of Spending on ACE Inhibitors vs Angiotensin-II Receptor Antagonists

0%

20%

40%

60%

80%

100%

Sep

-03

Dec-03

Mar-04

Jun

-04

Sep

-04

Dec-04

Mar-05

Jun

-05

Sep

-05

Dec-05

Mar-06

Jun

-06

Sep

-06

Dec-06

Mar-07

Jun

-07

Sep

-07

Dec-07

Mar-08

Jun

-08

Sep

-08

Quarter to

% o

f N

IC (

£)

ACE Inhibitors Angiotensin-II Receptor Antagonists

© Copyright NHSBSA 2009

Trends in Prescribing of ACE Inhibitors (including combinations) in General Practice in England

0

1,000,000

2,000,000

3,000,000

4,000,000

5,000,000

6,000,000

7,000,000

8,000,000

9,000,000

10,000,000

Sep

-03

Dec-03

Mar-04

Jun

-04

Sep

-04

Dec-04

Mar-05

Jun

-05

Sep

-05

Dec-05

Mar-06

Jun

-06

Sep

-06

Dec-06

Mar-07

Jun

-07

Sep

-07

Dec-07

Mar-08

Jun

-08

Sep

-08

Quarter to

Item

s

Ramipril Lisinopril Perindopril Enalapril Combinations Others

© Copyright NHSBSA 2009

Trends in Spending on ACE Inhibitors (including combinations) in General Practice in England

0

10,000,000

20,000,000

30,000,000

40,000,000

50,000,000

60,000,000

70,000,000

80,000,000

90,000,000

Sep

-03

Dec-03

Mar-04

Jun

-04

Sep

-04

Dec-04

Mar-05

Jun

-05

Sep

-05

Dec-05

Mar-06

Jun

-06

Sep

-06

Dec-06

Mar-07

Jun

-07

Sep

-07

Dec-07

Mar-08

Jun

-08

Sep

-08

Quarter to

NIC

(£)

Ramipril Lisinopril Perindopril Enalapril Combinations Others

© Copyright NHSBSA 2009

Trends in Prescribing of Angiotensin-II Receptor Antagonists (including combinations) in General Practice in England

0

500,000

1,000,000

1,500,000

2,000,000

2,500,000

3,000,000

3,500,000

4,000,000

Sep

-03

Dec-03

Mar-04

Jun

-04

Sep

-04

Dec-04

Mar-05

Jun

-05

Sep

-05

Dec-05

Mar-06

Jun

-06

Sep

-06

Dec-06

Mar-07

Jun

-07

Sep

-07

Dec-07

Mar-08

Jun

-08

Sep

-08

Quarter to

Item

s

Losartan Candesartan Irbesartan Valsartan Combinations Others

© Copyright NHSBSA 2009

Trends in Spending on Angiotensin-II Receptor Antagonists (including combinations) in General Practice in England

0

10,000,000

20,000,000

30,000,000

40,000,000

50,000,000

60,000,000

70,000,000

80,000,000

Sep

-03

Dec-03

Mar-04

Jun

-04

Sep

-04

Dec-04

Mar-05

Jun

-05

Sep

-05

Dec-05

Mar-06

Jun

-06

Sep

-06

Dec-06

Mar-07

Jun

-07

Sep

-07

Dec-07

Mar-08

Jun

-08

Sep

-08

Quarter to

NIC

(£)

Losartan Candesartan Irbesartan Valsartan Combinations Others

© Copyright NHSBSA 2009

Trends in Prescribing of Nitrates in General Practice in England

0

500,000

1,000,000

1,500,000

2,000,000

2,500,000

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Quarter to

Item

s

Isosorbide Mononitrate Glyceryl Trinitrate Isosorbide Dinitrate

© Copyright NHSBSA 2009

Trends in Spending on Nitrates in General Practice in England

0

2,000,000

4,000,000

6,000,000

8,000,000

10,000,000

12,000,000

14,000,000

16,000,000

18,000,000

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Quarter to

NIC

(£)

Isosorbide Mononitrate Glyceryl Trinitrate Isosorbide Dinitrate

© Copyright NHSBSA 2009

Trends in Prescribing of Calcium-channel Blockers in General Practice in England

0

1,000,000

2,000,000

3,000,000

4,000,000

5,000,000

6,000,000

7,000,000

8,000,000

Sep

-03

Dec-03

Mar-04

Jun

-04

Sep

-04

Dec-04

Mar-05

Jun

-05

Sep

-05

Dec-05

Mar-06

Jun

-06

Sep

-06

Dec-06

Mar-07

Jun

-07

Sep

-07

Dec-07

Mar-08

Jun

-08

Sep

-08

Quarter to

Item

s

Amlodipine Nifedipine DiltiazemFelodipine Lercanidipine Verapamil Others

© Copyright NHSBSA 2009

Trends in Spending on Calcium-channel Blockers in General Practice in England

0

10,000,000

20,000,000

30,000,000

40,000,000

50,000,000

60,000,000

70,000,000

80,000,000

90,000,000

Sep

-03

Dec-03

Mar-04

Jun

-04

Sep

-04

Dec-04

Mar-05

Jun

-05

Sep

-05

Dec-05

Mar-06

Jun

-06

Sep

-06

Dec-06

Mar-07

Jun

-07

Sep

-07

Dec-07

Mar-08

Jun

-08

Sep

-08

Quarter to

NIC

(£)

Amlodipine Nifedipine DiltiazemFelodipine Lercanidipine Verapamil Others

© Copyright NHSBSA 2009

Trends in Prescribing of and Spending on Nicorandil in General Practice in England

0

100,000

200,000

300,000

400,000

500,000

600,000

Sep

-03

Dec-03

Mar-04

Jun

-04

Sep

-04

Dec-04

Mar-05

Jun

-05

Sep

-05

Dec-05

Mar-06

Jun

-06

Sep

-06

Dec-06

Mar-07

Jun

-07

Sep

-07

Dec-07

Mar-08

Jun

-08

Sep

-08

Quarter to

Item

s

£0

£1,000,000

£2,000,000

£3,000,000

£4,000,000

£5,000,000

£6,000,000

£7,000,000

NIC

(£)

Items NIC

© Copyright NHSBSA 2009

Trends in Prescribing of Peripheral Vasodilators in General Practice in England

0

10,000

20,000

30,000

40,000

50,000

60,000

70,000

80,000

90,000

100,000

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Quarter to

Item

s

Naftidrofuryl Oxerutins Pentoxifylline Nicotinic Acid Derivatives Cilostazol Others

© Copyright NHSBSA 2009

Trends in Spending on Peripheral Vasodilators in General Practice in England

0

200,000

400,000

600,000

800,000

1,000,000

1,200,000

1,400,000

1,600,000

Sep

-03

Dec-03

Mar-04

Jun

-04

Sep

-04

Dec-04

Mar-05

Jun

-05

Sep

-05

Dec-05

Mar-06

Jun

-06

Sep

-06

Dec-06

Mar-07

Jun

-07

Sep

-07

Dec-07

Mar-08

Jun

-08

Sep

-08

Quarter to

NIC

(£)

Naftidrofuryl Oxerutins Pentoxifylline Nicotinic Acid Derivatives Cilostazol Others

© Copyright NHSBSA 2009

Trends in Prescribing of and Spending on Warfarin in General Practice in England

0

500,000

1,000,000

1,500,000

2,000,000

2,500,000

Sep

-03

Dec-03

Mar-04

Jun

-04

Sep

-04

Dec-04

Mar-05

Jun

-05

Sep

-05

Dec-05

Mar-06

Jun

-06

Sep

-06

Dec-06

Mar-07

Jun

-07

Sep

-07

Dec-07

Mar-08

Jun

-08

Sep

-08

Quarter to

Item

s

£0

£1,000,000

£2,000,000

£3,000,000

£4,000,000

£5,000,000

£6,000,000

£7,000,000

NIC

(£)

Items NIC (£)

© Copyright NHSBSA 2009

Trends in Prescribing of Antiplatelet Drugs in General Practice in England

0

2,000,000

4,000,000

6,000,000

8,000,000

10,000,000

12,000,000

Sep

-03

Dec-03

Mar-04

Jun

-04

Sep

-04

Dec-04

Mar-05

Jun

-05

Sep

-05

Dec-05

Mar-06

Jun

-06

Sep

-06

Dec-06

Mar-07

Jun

-07

Sep

-07

Dec-07

Mar-08

Jun

-08

Sep

-08

Quarter to

Item

s

Aspirin Clopidogrel Dipyridamole Others

© Copyright NHSBSA 2009

Trends in Spending on Antiplatelet Drugs in General Practice in England

0

10,000,000

20,000,000

30,000,000

40,000,000

50,000,000

60,000,000

Sep

-03

Dec-03

Mar-04

Jun

-04

Sep

-04

Dec-04

Mar-05

Jun

-05

Sep

-05

Dec-05

Mar-06

Jun

-06

Sep

-06

Dec-06

Mar-07

Jun

-07

Sep

-07

Dec-07

Mar-08

Jun

-08

Sep

-08

Quarter to

NIC

(£)

Aspirin Clopidogrel Dipyridamole Others

© Copyright NHSBSA 2009

Trends in Prescribing of Aspirin BNF 2.9 (E/C Tablets vs Other Formulations) in General Practice in England

0

1,000,000

2,000,000

3,000,000

4,000,000

5,000,000

6,000,000

7,000,000

8,000,000

9,000,000

Sep

-03

Dec-03

Mar-04

Jun

-04

Sep

-04

Dec-04

Mar-05

Jun

-05

Sep

-05

Dec-05

Mar-06

Jun

-06

Sep

-06

Dec-06

Mar-07

Jun

-07

Sep

-07

Dec-07

Mar-08

Jun

-08

Sep

-08

Quarter to

Item

s

Others E/C

© Copyright NHSBSA 2009

Trends in Spending on Aspirin BNF 2.9 (E/C Tablets vs Other Formulations) in General Practice in England

0

2,000,000

4,000,000

6,000,000

8,000,000

10,000,000

12,000,000

14,000,000

16,000,000

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Quarter to

NIC

(£)

Others E/C

© Copyright NHSBSA 2009

Trends in Prescribing of Lipid-regulating Drugs (excluding Statins) in General Practice in England

0

50,000

100,000

150,000

200,000

250,000

300,000

350,000

400,000

450,000

Sep

-03

Dec-03

Mar-04

Jun

-04

Sep

-04

Dec-04

Mar-05

Jun

-05

Sep

-05

Dec-05

Mar-06

Jun

-06

Sep

-06

Dec-06

Mar-07

Jun

-07

Sep

-07

Dec-07

Mar-08

Jun

-08

Sep

-08

Quarter to

Item

s

Bezafibrate Fenofibrate Omega-3 Ciprofibrate Colestyramine Others

NB. Excluding Ezetimibe

© Copyright NHSBSA 2009

Trends in Spending on Lipid-regulating Drugs (excluding Statins) in General Practice in England

0

1,000,000

2,000,000

3,000,000

4,000,000

5,000,000

6,000,000

7,000,000

8,000,000

9,000,000

Sep

-03

Dec-03

Mar-04

Jun

-04

Sep

-04

Dec-04

Mar-05

Jun

-05

Sep

-05

Dec-05

Mar-06

Jun

-06

Sep

-06

Dec-06

Mar-07

Jun

-07

Sep

-07

Dec-07

Mar-08

Jun

-08

Sep

-08

Quarter to

NIC

(£)

Bezafibrate Fenofibrate Omega-3 Ciprofibrate Colestyramine Others

NB. Excluding Ezetimibe

© Copyright NHSBSA 2009

Trends in Prescribing of and Spending on Ezetimibe in General Practice in England

0

100,000

200,000

300,000

400,000

500,000

600,000

Sep

-03

Dec-03

Mar-04

Jun

-04

Sep

-04

Dec-04

Mar-05

Jun

-05

Sep

-05

Dec-05

Mar-06

Jun

-06

Sep

-06

Dec-06

Mar-07

Jun

-07

Sep

-07

Dec-07

Mar-08

Jun

-08

Sep

-08

Quarter to

Item

s

£0

£2,000,000

£4,000,000

£6,000,000

£8,000,000

£10,000,000

£12,000,000

£14,000,000

£16,000,000

£18,000,000

£20,000,000

NIC

(£)

Items NIC (£)

© Copyright NHSBSA 2009

Trends in Prescribing of Fibrates in General Practice in England

0

50,000

100,000

150,000

200,000

250,000

300,000

Sep

-03

Dec-03

Mar-04

Jun

-04

Sep

-04

Dec-04

Mar-05

Jun

-05

Sep

-05

Dec-05

Mar-06

Jun

-06

Sep

-06

Dec-06

Mar-07

Jun

-07

Sep

-07

Dec-07

Mar-08

Jun

-08

Sep

-08

Quarter to

Item

s

Bezafibrate Fenofibrate Ciprofibrate Gemfibrozil

© Copyright NHSBSA 2009

Trends in Spending on Fibrates in General Practice in England

0

500,000

1,000,000

1,500,000

2,000,000

2,500,000

3,000,000

3,500,000

4,000,000

4,500,000

Sep

-03

Dec-03

Mar-04

Jun

-04

Sep

-04

Dec-04

Mar-05

Jun

-05

Sep

-05

Dec-05

Mar-06

Jun

-06

Sep

-06

Dec-06

Mar-07

Jun

-07

Sep

-07

Dec-07

Mar-08

Jun

-08

Sep

-08

Quarter to

NIC

(£)

Bezafibrate Fenofibrate Ciprofibrate Gemfibrozil

© Copyright NHSBSA 2009

Trends in Prescribing of Nicotinic Acid Group Drugs in General Practice in England

0

1,000

2,000

3,000

4,000

5,000

6,000

7,000

8,000

9,000

10,000

Sep

-03

Dec-03

Mar-04

Jun

-04

Sep

-04

Dec-04

Mar-05

Jun

-05

Sep

-05

Dec-05

Mar-06

Jun

-06

Sep

-06

Dec-06

Mar-07

Jun

-07

Sep

-07

Dec-07

Mar-08

Jun

-08

Sep

-08

Quarter to

Item

s

Nicotinic Acid Acipimox

© Copyright NHSBSA 2009

Trends in Spending on Nicotinic Acid Group Drugs in General Practice in England

0

50,000

100,000

150,000

200,000

250,000

300,000

Sep

-03

Dec-03

Mar-04

Jun-04

Sep

-04

Dec-04

Mar-05

Jun-05

Sep

-05

Dec-05

Mar-06

Jun-06

Sep

-06

Dec-06

Mar-07

Jun-07

Sep

-07

Dec-07

Mar-08

Jun-08

Sep

-08

Quarter to

NIC

(£)

Nicotinic Acid Acipimox

© Copyright NHSBSA 2009

Trends in Prescribing of Statins in General Practice in England

0

2,000,000

4,000,000

6,000,000

8,000,000

10,000,000

12,000,000

14,000,000

Sep

-03

Dec-03

Mar-04

Jun

-04

Sep

-04

Dec-04

Mar-05

Jun

-05

Sep

-05

Dec-05

Mar-06

Jun

-06

Sep

-06

Dec-06

Mar-07

Jun

-07

Sep

-07

Dec-07

Mar-08

Jun

-08

Sep

-08

Quarter to

Item

s

Simvastatin Atorvastatin Pravastatin Rosuvastatin Others

© Copyright NHSBSA 2009

Trends in Spending on Statins in General Practice in England

0

50,000,000

100,000,000

150,000,000

200,000,000

Sep

-03

Dec-03

Mar-04

Jun

-04

Sep

-04

Dec-04

Mar-05

Jun

-05

Sep

-05

Dec-05

Mar-06

Jun

-06

Sep

-06

Dec-06

Mar-07

Jun

-07

Sep

-07

Dec-07

Mar-08

Jun

-08

Sep

-08

Quarter to

NIC

(£)

Simvastatin Atorvastatin Pravastatin Rosuvastatin Others

© Copyright NHSBSA 2009

Trends in Prescribing of Atorvastatin Tabs by Strength in General Practice in England

0

200,000

400,000

600,000

800,000

1,000,000

1,200,000

1,400,000

1,600,000

1,800,000

Sep

-03

Dec-03

Mar-04

Jun

-04

Sep

-04

Dec-04

Mar-05

Jun

-05

Sep

-05

Dec-05

Mar-06

Jun

-06

Sep

-06

Dec-06

Mar-07

Jun

-07

Sep

-07

Dec-07

Mar-08

Jun

-08

Sep

-08

Quarter to

Item

s

10mg 20mg 40mg 80mg

© Copyright NHSBSA 2009

Trends in Spending on Atorvastatin Tabs by Strength in General Practice in England

0

5,000,000

10,000,000

15,000,000

20,000,000

25,000,000

30,000,000

35,000,000

40,000,000

45,000,000

Sep

-03

Dec-03

Mar-04

Jun

-04

Sep

-04

Dec-04

Mar-05

Jun

-05

Sep

-05

Dec-05

Mar-06

Jun

-06

Sep

-06

Dec-06

Mar-07

Jun

-07

Sep

-07

Dec-07

Mar-08

Jun

-08

Sep

-08

Quarter to

NIC

(£)

10mg 20mg 40mg 80mg

© Copyright NHSBSA 2009

Trends in Prescribing of Simvastatin Tabs by Strength in General Practice in England

0

1,000,000

2,000,000

3,000,000

4,000,000

5,000,000

6,000,000

Sep

-03

Dec-03

Mar-04

Jun

-04

Sep

-04

Dec-04

Mar-05

Jun

-05

Sep

-05

Dec-05

Mar-06

Jun

-06

Sep

-06

Dec-06

Mar-07

Jun

-07

Sep

-07

Dec-07

Mar-08

Jun

-08

Sep

-08

Quarter to

Item

s

10mg 20mg 40mg 80mg

© Copyright NHSBSA 2009

Trends in Spending on Simvastatin Tabs by Strength in General Practice in England

0

5,000,000

10,000,000

15,000,000

20,000,000

25,000,000

30,000,000

35,000,000

40,000,000

45,000,000

Sep

-03

Dec-03

Mar-04

Jun

-04

Sep

-04

Dec-04

Mar-05

Jun

-05

Sep

-05

Dec-05

Mar-06

Jun

-06

Sep

-06

Dec-06

Mar-07

Jun

-07

Sep

-07

Dec-07

Mar-08

Jun

-08

Sep

-08

Quarter to

NIC

(£)

10mg 20mg 40mg 80mg

© Copyright NHSBSA 2009

Trends in Prescribing of Rosuvastatin by Strength in General Practice in England

0

50,000

100,000

150,000

200,000

250,000

300,000

350,000

Sep

-03

Dec-03

Mar-04

Jun

-04

Sep

-04

Dec-04

Mar-05

Jun

-05

Sep

-05

Dec-05

Mar-06

Jun

-06

Sep

-06

Dec-06

Mar-07

Jun

-07

Sep

-07

Dec-07

Mar-08

Jun

-08

Sep

-08

Quarter to

Item

s

5mg 10mg 20mg 40mg

© Copyright NHSBSA 2009

Trends in Spending on Rosuvastatin by Strength in General Practice in England

0

1,000,000

2,000,000

3,000,000

4,000,000

5,000,000

6,000,000

7,000,000

8,000,000

Sep-03

Dec-03

Mar-04

Jun-04

Sep-04

Dec-04

Mar-05

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Quarter to

NIC

(£)

5mg 10mg 20mg 40mg

© Copyright NHSBSA 2009

Trends in Prescribing of and Spending on Inegy® in General Practice in England

0

10,000

20,000

30,000

40,000

50,000

60,000

Jun-05

Sep-05

Dec-05

Mar-06

Jun-06

Sep-06

Dec-06

Mar-07

Jun-07

Sep-07

Dec-07

Mar-08

Jun-08

Sep-08

Quarter to

Item

s

£0

£500,000

£1,000,000

£1,500,000

£2,000,000

£2,500,000

£3,000,000

NIC

(£)

Items NIC

© Copyright NHSBSA 2009

% Ratio of Prescribing of High Strength Statins (Atorvastatin 40mg / 80mg, Rosuvastatin 20mg / 40mg, Simvastatin 80mg and Inegy®)

vs All Other Statins in General Practice in England

0%

20%

40%

60%

80%

100%

Sep

-03

Dec-03

Mar-04

Jun

-04

Sep

-04

Dec-04

Mar-05

Jun

-05

Sep

-05

Dec-05

Mar-06

Jun

-06

Sep

-06

Dec-06

Mar-07

Jun

-07

Sep

-07

Dec-07

Mar-08

Jun

-08

Sep

-08

Quarter to

% o

f It

ems

All other Statins High Strength

© Copyright NHSBSA 2009

% Ratio of Spending on High Strength Statins (Atorvastatin 40mg / 80mg, Rosuvastatin 20mg / 40mg, Simvastatin 80mg and Inegy®)

vs All Other Statins in General Practice in England

0%

20%

40%

60%

80%

100%

Sep

-03

Dec-03

Mar-04

Jun

-04

Sep

-04

Dec-04

Mar-05

Jun

-05

Sep

-05

Dec-05

Mar-06

Jun

-06

Sep

-06

Dec-06

Mar-07

Jun

-07

Sep

-07

Dec-07

Mar-08

Jun

-08

Sep

-08

Quarter to

% o

f N

IC (

£)

All other Statins High Strength

© Copyright NHSBSA 2009